Subscribe
servickuz
servickuz / shutterstock.com
14 January 2020EuropeRory O'Neill

EPO appeals board weighs-up Broad’s CRISPR claims

The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing
4 November 2019   The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

More on this story

Biotechnology
EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing
4 November 2019   The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

More on this story

Biotechnology
EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing
4 November 2019   The Board of Appeal of the European Patent Office has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud
US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug